Regadenoson Impurity32;871108-08-6

Details:

Regadenoson Impurity;871108-08-6

Product Information (R013032)

• Product Code：R013032

• English Name：Regadenoson Impurity 32

• English Alias：(2R,3R,4S,5R)-2-(2,6-dihydrazinyl-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

• CAS No.：871108-08-6

• Molecular Formula：C??H??N?O?

• Molecular Weight：312.29

Advantages (R013032)

• High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for Regadenoson hydrazine impurity analysis and quality control.

• Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.3% in methanol-water mixture within 6 months.

Applications (R013032)

• Quality Control Testing：Used for UPLC-MS/MS detection of Impurity 32 in Regadenoson API and formulations, controlling content to meet ICH Q3A standards (single impurity limit ≤0.1%).

• Process Optimization Research：Monitors impurity formation during Regadenoson synthesis, reducing generation by >35% by adjusting hydrazination temperature (e.g., 40-50℃) and pH.

• Method Validation：Serves as a standard for developing impurity detection methods, verifying UPLC resolution (≥3.0) and LOD (0.01 ng/mL).

Background Description (R013032)

Regadenoson, a selective A2A adenosine receptor agonist, is used for myocardial perfusion imaging. Impurity 32, a hydrazine-related impurity in its synthesis, may originate from hydrazination side reactions of purine rings or raw material residues. Its hydrazine, purine ring, and polyol groups may affect drug stability, receptor binding, and safety. Due to strict impurity control requirements for cardiovascular drugs, studying this impurity is crucial for ensuring drug quality.

Research Status (R013032)

• Detection Technology：UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 8 minutes, with LOD of 0.005 ng/mL for trace impurity analysis.

• Formation Mechanism：Formed by substitution of 2,6-dichloropurine with hydrazine compounds under alkaline conditions (e.g., sodium carbonate/methanol system); optimizing reaction pH and hydrazine dosage inhibits side reactions.

• Safety Evaluation：In vitro cytotoxicity shows IC?? of 192.7 μM against H9c2 cardiac cells (Regadenoson IC??=8.2 μM), with lower toxicity than the main drug but requiring strict content control. Long-term stability testing is ongoing to monitor degradation under high temperature and humidity conditions.

NOTE！